Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Springfield, MA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Springfield, MA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Waltham, MA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Waltham, MA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Bloomington, MN
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Bloomington, MN
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Duluth, MN
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Duluth, MN
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Minneapolis, MN
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Tupelo, MS
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Tupelo, MS
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Jefferson City, MO
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Kansas City, MO
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Kansas City, MO
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Butte, MT
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Butte, MT
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Omaha, NE
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Dover, NH
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Dover, NH
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Hampton, NH
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Hampton, NH
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Lawrenceville, NJ
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Lawrenceville, NJ
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Albany, NY
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Albany, NY
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
New Hyde Park, NY
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Rochester, NY
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Asheville, NC
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Asheville, NC
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Greenville, NC
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Greenville, NC
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Cincinnati, OH
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Cleveland, OH
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Dayton, OH
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Dayton, OH
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Kettering, OH
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Kettering, OH
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Mentor, OH
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Mentor, OH
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Medford, OR
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Medford, OR
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Hershey, PA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Hershey, PA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Norristown, PA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Norristown, PA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Philadelphia, PA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Chattanooga, TN
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Dallas, TX
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Midland, TX
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Midland, TX
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
San Antonio, TX
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Ogden, UT
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Ogden, UT
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Olympia, WA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Olympia, WA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Renton, WA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Renton, WA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Spokane, WA
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Milwaukee, WI
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Victoria,
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Victoria,
Click here to add this to my saved trials
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Saint Louis, MO
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Ozark, AL
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Ozark, AL
Click here to add this to my saved trials
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Tuscaloosa, AL
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Tucson, AZ
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Little Rock, AR
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Bermuda Dunes, CA
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Bermuda Dunes, CA
Click here to add this to my saved trials
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Escondido, CA
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Escondido, CA
Click here to add this to my saved trials
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Fresno, CA
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Fresno, CA
Click here to add this to my saved trials
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Huntington Beach, CA
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
La Jolla, CA
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
La Jolla, CA
Click here to add this to my saved trials
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Northridge, CA
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Northridge, CA
Click here to add this to my saved trials
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Orange, CA
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Poway, CA
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
Effect of Inhaled Insulin (AERx® iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Poway, CA
Click here to add this to my saved trials